{{Rsnum
|rsid=4742
|Gene=DCTD
|Chromosome=4
|position=182894535
|Orientation=minus
|GMAF=0.2975
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=DCTD
}}{{PharmGKB
|RSID=rs4742
|Name_s=DCTD:315T>C, 348T>C, mRNA 512T>C, mRNA 489T>C, V105V, V116V
|Gene_s=DCTD
|Feature=Exon/Syn
|Evidence=PubMed ID:15224082
|Annotation=Risk or phenotype-associated allele: None. Phenotype: Variants identified in a screen of 13 genes involved in the gemcitabine drug metabolic pathway. For the synonymous DCTD:315T>C (V105V, V116V) SNP, the C allele was at frequency 0.25 and 0.48 in Europeans and Africans, respectively. There was a significant difference between ethnic groups in genotype frequency distribution (p < 0.001). Study size: 186. Study population/ethnicity: Healthy, unrelated blood donors of European (n = 92) and African (n = 94) descent. Significance metric(s): p < 0.001. Type of association: GN.
|Drugs=gemcitabine
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA165110718
}}

{{ population diversity
| geno1 = (A;A)
| geno2 = (A;G)
| geno3 = (G;G)
| CEU | 46.0 | 38.9 | 15.0
| CHB | 67.4 | 27.9 | 4.7
| JPT | 67.1 | 30.6 | 2.4
| YRI | 21.2 | 46.0 | 32.7
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs4742
|overall_frequency_n=4087
|overall_frequency_d=10758
|overall_frequency=0.379903
|n_genomes=29
|n_genomes_annotated=0
|n_haplomes=36
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}